Management of mTOR Inhibitor Side Effects

Patricia A. Creel

treatment, drug therapy
CJON 2009, 13(6), 19-23. DOI: 10.1188/09.CJON.S2.19-23

Although surgery remains the primary curative treatment for renal cell carcinoma (RCC), systemic therapy also is indicated in the advanced disease setting. This article reviews the role of mammalian target of rapamycin inhibitors in the treatment of metastatic RCC. A case study is presented to illustrate side-effect management issues commonly encountered by oncology nurses in clinical practice.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.